# Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia

> **NCT01039363** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat

## Key facts

- **NCT ID:** NCT01039363
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2009-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039363, "Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01039363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*